| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802681701034 | 268170103 | EMSELEX PR.TAB 7,5 MG/TAB BTx28 σε BLISTERS PVC/CTFE/ALU PVC/CTFE/ALU | 11.55 | 12.12 | 16.71 |
| 05/2018 | 2802681702031 | 268170203 | EMSELEX PR.TAB 15MG/TAB BTx28 σε BLISTERS PVC/CTFE/ALU PVC/CTFE/ALU | 19.30 | 20.25 | 27.91 |
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
Darifenacin selectively antagonizes the muscarinic M3 receptor. M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function.
Overdosage can potentially result in severe central anticholinergic effects.
The mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.
The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.
* 163 L
* 40 L/h [extensive metabolizers] * 32 L/h [poor metabolizers]